相关实验视频
Updated: Jun 11, 2025

Comprehensive Analysis of Drug Response using the FLICK Assay
Published on: June 6, 2025
基于FDA不良事件报告系统的reslizumab的不成比例分析
Huqun Li1, Cuilian Guo2, Chongshu Wang2
1Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China.
对重症喘治疗reslizumab的现实世界分析发现常见的不良事件如呼吸障碍和口腔关节疼痛. 还注意到了气管和胸痛等意想不到的事件,以及对药物无效的担忧.
科学领域:
- 药物监督 药物监督 药物监督
- 现实世界的证据.
- 药物安全分析 药物安全分析
背景情况:
- 增加使用reslizumab治疗具有eosinophilic表型的严重喘.
- 需要现实世界的药物监测来识别未报告的不良事件 (AE).
研究的目的:
- 在现实临床实践中对与reslizumab相关的副作用进行全面评估.
- 评估reslizumab的安全概况.
主要方法:
- 使用FDA不良事件报告系统 (FAERS) 数据库进行不成比例分析.
- 从2016年第二季度到2022年第四季度对与reslizumab相关的副作用的分析.
- 使用报告几率比 (ROR) 进行信号检测.
主要成果:
- 分析了来自FAERS的10,450,353份报告.
- 在403个与reslizumab相关的AE中,确定了42个具有积极信号的独特AE.
- 常见的AE:呼吸不全,口腔喉疼痛. 意想不到的副作用:支气管,胸痛.
- 在13.90%的病例中报告了药物无效.
结论:
- 雷斯利祖马布是一种有前途的治疗方法,用于治疗严重的酸性喘.
- 需要注意常见和意想不到的AE.
- 需要进一步的前性研究来验证信号.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Relative Risk
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Hazard Ratio
For example, in a clinical trial...
Drug Regulation